ArticleDiscover oncology2025
Development and explanation of a machine learning model for identifying non-localized early-onset T1 colorectal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFor patients with early-onset T1 colorectal cancer (CRC), it is crucial to perform radical resection with minimal tissue damage. This study aims to develop and elucidate a machine learning model for the identification of non-located early-onset T1 CRC.
methodsWe extracted relevant data from the Surveillance, Epidemiology, and End Results (SEER) database and randomly allocated patients into a training set and a validation set. Five machine learning models were utilized: extreme gradient boosting (XGBoost), support vector machine (SVM), random forest (RF), decision tree (DT), and logistic regression (LR) were developed for the tumor metastasis status prediction. Area under the receiver operating characteristic curve (AUC) and confusion matrix were used to evaluate the model. The Shapley Additive Explanations (SHAP) method was employed as the primary technique for model explanation.
resultsA cohort of 1,878 patients was selected according to predefined inclusion and exclusion criteria. The XGBoost model was selected for its favorable performance, with an AUC of 0.755 and accuracy of 0.833 in the validation cohort. Significant risk factors, identified by SHAP values greater than 0.1 for non-localized T1 tumors, included carcinoembryonic antigen (CEA) levels exceeding 5 ng/mL, tumor size greater than 5 cm, mucinous adenocarcinoma, signet-ring cell adenocarcinoma, tumor location in the left colon, and poorly differentiated or undifferentiated histological grades. Additionally, black race, a diagnostic-to-surgical interval exceeding one month and PNI may represent potential risk factors.
conclusionThe XGBoost model holds the potential to assist clinicians in evaluating and selecting optimal treatment strategies for patients with early-onset T1 CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.